Name | VU0467154 |
Description | VU0467154 is a positive allosteric modulator of the M4 muscarinic acetylcholine receptor (M4 mAChR). |
In vitro | VU0467154 potentiates the response to ACh with pEC50s of 7.75(rat), 6.2(human) and 6(cynomolgus monkey) for M4 receptor, respectively. VU0467154 does not potentiate the ACh response at rat and human M1, M2, M3, or M5[1]. |
In vivo | VU0467154 produced a robust dose-dependent reversal of MK-801-induced hyperlocomotion and deficits in preclinical models of associative learning and memory functions, including the touchscreen pairwise visual discrimination task in wild-type mice, but failed to reverse these stimulant-induced deficits in M4 KO mice[1]. VU0467154 also enhanced the acquisition of both contextual and cue-mediated fear conditioning when administered alone in wild-type mice[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 55 mg/mL (123.75 mM), Sonication is recommended.
|
Keywords | VU 0467154 | Muscarinic acetylcholine receptor | VU0467154 | VU-0467154 | mAChR | inhibit | Inhibitor |
Inhibitors Related | Adiphenine hydrochloride | Nanofin | Arecoline hydrobromide | Forskolin | Pilocarpine Hydrochloride | CLOZAPINE N-OXIDE | Pilocarpine nitrate | Ribavirin | Adenine | Amitriptyline hydrochloride | Choline chloride | Propoxur |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Anti-Alzheimer's Disease Compound Library | Membrane Protein-targeted Compound Library | Anti-Parkinson's Disease Compound Library | Neurotransmitter Receptor Compound Library | Bioactive Compounds Library Max |